DB15799Experimental
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine... The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation.
- Code names
- LNP-nCoVsaRNA Vaccine
What you can answer from here — as of March 06, 2025
Which companies are running trials of LNP-nCoVsaRNA Vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account